Business and Finance
Amic is developing technology that uses a chip-based micro-fluidic platform to enable fully quantitative, immunoassay tests in POC or near-patient settings. This next-generation technology represents an advance in an area of diagnostics where double-digit market growth is anticipated.
"This acquisition is a strategic opportunity to develop a Point-of-Care
channel," said
"We're excited about the possibilities of touching the lives of patients
by combining our testing technologies with current and future assays of
Ortho-Clinical Diagnostics," said
About Johnson & Johnson Nordic AB
Johnson & Johnson Nordic AB is a subsidiary of Johnson & Johnson. Based in
Sollentuna,
About Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, delivers high quality in vitro diagnostic products that give health care professionals around the world the knowledge they need to make better treatment decisions sooner. The company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that's safe, the right type, and the right unit. Ortho-Clinical Diagnostics also brings sophisticated information management, testing technologies, automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care. For more information, visit www.orthoclinical.com.
(This press release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements are
based on current expectations of future events. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize, actual results
could vary materially from Johnson & Johnson's expectations and projections.
Risks and uncertainties include general industry conditions and competition;
economic conditions, such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approvals; domestic and foreign health care reforms and governmental laws and
regulations; and trends toward health care cost containment. A further list
and description of these risks, uncertainties and other factors can be found
in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year
ended
SOURCE Johnson & Johnson Nordic AB
|
|